Tools chosen: kalshi_direct kalshi_related polymarket_related claude_news gdelt_news wikipedia code_execution

Sub-questions (Fermi decomposition)

Planner reasoning

This is a Kalshi question about whether Finnish smart-ring maker Oura (Oura Health Oy) officially announces an IPO before Oct 1, 2026. The key drivers are: Oura's recent funding rounds and valuation, any public statements from CEO Tom Hale about IPO timing, whether a confidential S-1/F-1 or listing filing has occurred, and the general 2026 IPO window. Primary anchor is the Kalshi market price itself, supplemented by news search for IPO signals.

# Current state Oura Health Oy confidentially filed for a US IPO with the SEC on 2026-05-21 (confirmed by company statement, Bloomberg/CNBC/Forbes), with bankers (Goldman, Morgan Stanley, JPMorgan, Allen & Co., Jefferies) reportedly mandated and a "later in 2026" listing target cited by sources familiar with the matter. However, no public S-1, pricing, or actual exchange debut has occurred as of the latest data (mid-Aug 2026), and Kalshi's own price has collapsed from a 57% high to 15%, suggesting the market does not treat the confidential filing alone as satisfying "officially announce an IPO" and doubts a fuller public confirmation will land before Oct 1, 2026. # Timeline of key events - 2024-12: Series D, $200M raised, $5.2B valuation, Dexcom/Fidelity participate (confirmed, TechCrunch/Fierce Healthcare). - 2025-10-14: Series E, $900M+ raised, $11B valuation, led by Fidelity w/ ICONIQ, Whale Rock, Atreides (confirmed, CNBC). - 2025 (late): CEO Tom Hale, asked about IPO, cites Stripe/SpaceX staying-private advantages but doesn't rule it out (reported). - 2026-03: Reports Oura began interviewing investment bankers (reported, PYMNTS). - 2026-05-21: Oura confirms confidential SEC filing for US IPO; underwriters named; "later this year" listing floated by person familiar w/ matter (confirmed by company, multiple outlets: Bloomberg, CNBC, Forbes). - 2026-05-25/28: Euronews/Guardian frame Oura as "heading towards IPO" alongside Ring 5 launch (reported, not new structural fact). - 2026-06: Modern Healthcare notes 2026 has been "quieter" than expected for digital-health IPO exits despite tailwinds (reported). - 2026-06 to 2026-08: Continued product coverage (Ring 5 reviews) with no further IPO milestone reported; no S-1 public filing, pricing, or listing confirmed as of latest GDELT data (2026-08-14). # Event Will Oura Health Oy officially announce an IPO before Oct 1, 2026 (Kalshi KXIPOOURA-26OCT01)? # Outcomes to forecast Yes / No # Kalshi market anchor Current YES price: **15%** (as of latest data). Trend: -20% over 7 days, -42% over 30 days — sharp decline from a peak of 57% down to a low of 9%, now at 15%. Average daily volume ~206 contracts over 26 days. This is a clear downward-trending market pricing IPO-announcement risk as low and falling. # Sub-question answers 1. **Kalshi price/90-day move** — Currently 15%, range 9-57% over the observed window; down sharply (-42% in 30 days), implying the market spiked on the May confidential-filing news then faded as no further public confirmation followed. [kalshi_direct] 2. **Public statements on IPO timing** — Hale (late 2025) acknowledged IPO optionality but emphasized staying-private advantages; by March 2026 Oura was reportedly interviewing bankers; company officially confirmed a confidential SEC filing on 2026-05-21, targeting a listing "later this year" per sources, but no specific date given. [claude_news, Forbes, PYMNTS] 3. **Most recent funding round** — Series E, Oct 2025, $900M+ raised at $11B valuation, led by Fidelity w/ ICONIQ, Whale Rock, Atreides. Total raised ~$1.5-2B lifetime. Fresh capital typically reduces urgency for near-term IPO, though here the company pursued a filing anyway ~7 months later. [CNBC, claude_news] 4. **Registration filings** — Yes: Oura confirmed a confidential SEC filing (US) on 2026-05-21. No evidence of Nasdaq Helsinki or other exchange filings. [Bloomberg/CNBC/Forbes] 5. **Base rate for late-stage unicorn IPO announcement in ~10-month window** — Generic hazard-rate model (ignoring the actual filing news) gives ~5-8% central estimate. This is now superseded by the structural fact of an actual confidential filing already in hand, which meaningfully raises probability above the generic base rate. [code_execution] 6. **2026 IPO pipeline/comparables** — 2026 IPO pipeline "surging" per Forbes (SpaceX, OpenAI mentioned), but Modern Healthcare (June 2026) notes digital-health exits have been "quieter" than hoped. Comparable peers: Strava confidentially filed Jan 2026 targeting 2026 listing; WHOOP ($10.1B valuation) signaling IPO intent via hiring drive. Cluster of sports/health-tech IPOs queuing for limited investor demand. [the5krunner, Modern Healthcare] # Key facts (high-confidence, factual) 1. [Bloomberg/CNBC/Forbes, 2026-05-21] Oura confirmed a confidential SEC IPO filing. 2. [CNBC, 2025-10-14] Series E: $900M+ at $11B valuation. 3. [Wikipedia] Oura is Finnish-founded (2013), HQ San Francisco, CEO Tom Hale since 2022. 4. [Modern Healthcare, 2026-06] No digital-health IPO has actually priced/listed by mid-2026 despite pipeline talk. 5. [Kalshi] Market price fell from 57% peak to 15%, signaling fading conviction in a formal announcement by Oct 1. # Cross-market signals - Kalshi related: Bloomberg IPO market at 6%, Airtable at 9%, Perplexity at 52% (all far-dated) — shows Kalshi generally prices most private-company IPO-announcement markets low unless filing is imminent. - Polymarket: No matching markets found. - Sportsbook implied: N/A (not applicable to this event type). # Analyst opinions and speculation - Bloomberg/Forbes sources (unnamed, "person familiar with the matter") suggest listing "later this year" with named underwriters — speculative but from credible reporting. - Market commentary (per claude_news) cautions confidential filings don't guarantee an IPO; firms can pull back amid soft windows. - the5krunner frames a "cluster" of sports-tech IPOs competing for limited investor demand, implying execution risk/delay. # Directional lean per outcome - **Yes**: Confidential SEC filing already confirmed; bankers named; company revenue growing fast ($1B→$2B); competitive pressure from Strava/WHOOP could push Oura to move quickly to capture window. - **No**: No public S-1/pricing yet as of Aug 2026; Kalshi price has fallen sharply post-news, implying market skepticism; "quieter" 2026 digital-health IPO environment; SEC confidential review timelines often extend 3-6+ months before public filing, which could push past Oct 1; ambiguity whether confidential filing alone meets "officially announce" bar. # Gaps / unknowns - Unclear whether Kalshi's resolution criterion treats the May confidential filing as satisfying "confirms an IPO" — if so, market may be mispriced too low; if a public S-1/roadshow/pricing is required, 15% may be roughly fair or even high. - No confirmation of exact SEC review timeline or roadshow date. - Reason for the 42% price drop over 30 days is not directly explained in sourced news — could reflect resolution-criteria clarification or fading follow-through news. # Calibration anchors - Kalshi current YES price: **15%** (down from 57% peak) — primary anchor. - Generic base rate for late-stage unicorn IPO announcement in 10-month window: ~5-8% (pre-filing), but should be adjusted upward given the already-confirmed confidential filing — situates fair value plausibly in the 15-30% range absent further confirmation, consistent with current market pricing near the low end of that band.

1. Both forecasts converge on identical 18% despite ostensibly independent reasoning, both landing modestly above the 15% anchor with nearly identical logic chains — this suggests anchoring bias/insufficient independent analysis rather than genuinely triangulated estimates; neither explores whether the "correct" answer could be meaningfully below 15% (i.e., that the confidential filing already happened and further public confirmation is unlikely in a "quiet" IPO window, per Modern Healthcare) or meaningfully above it. 2. Neither forecast seriously grapples with the resolution-criteria ambiguity flagged in the brief: "Unclear whether Kalshi's resolution criterion treats the May confidential filing as satisfying 'confirms an IPO'" — if the confidential filing itself counts as an "official announcement," this event may have already resolved YES in spirit, and the 15% market price reflects a different (stricter) reading that the forecasters simply defer to without independently weighing the alternative interpretation's probability mass. 3. Both forecasts treat the Kalshi price drop from 57%→15% as confirming a stricter resolution bar, but the brief itself notes "the reason for the 42% price drop... is not directly explained" and could instead reflect generic fading of retail attention or unrelated liquidity dynamics — neither forecaster flags this as a live alternative explanation that would argue for less deference to the price trend. 4. The competitive-pressure argument (Strava confidentially filed Jan 2026, WHOOP signaling IPO intent) is listed as a "Yes" driver in the brief but is invoked by both forecasters only as a "No" factor (crowded queue/limited demand) — the possibility that competitive urgency could accelerate Oura's public filing timeline to avoid being last-to-market is underweighted by both. 5. Neither forecast quantifies the specific ~6-week runway (mid-Aug to Oct 1) against typical confidential-to-public S-1 conversion timelines; the brief notes "SEC confidential review timelines often extend 3-6+ months," which — if taken literally from the May 21 filing — would put public filing around Aug-Nov 2026, arguably placing meaningful probability mass right at the edge of the window, warranting more explicit scenario-based dating rather than a flat adjustment above the anchor. 6. Both forecasts cite the same cross-market comparables (Bloomberg 6%, Airtable 9%) as supportive of staying low, but neither notes these are "far-dated" per the brief while Oura already has a live confidential filing — a materially different structural position that arguably justifies pricing well above these comparables rather than treating them as a ceiling.

19% (56% confidence)

Yes: 19% No: 81%

The 15% Kalshi anchor is the strongest signal, and its collapse from 57% after the May confidential-filing news most plausibly reflects traders learning that a confidential filing does not satisfy the resolution bar — an inference reinforced by the market failing to re-rate upward over three months. Against that, Oura genuinely has a live confidential filing with named underwriters and a reported 'later in 2026' listing target, which structurally distinguishes it from far-dated comparables (Bloomberg 6%, Airtable 9%) and puts it well above the 5–8% generic base rate; a public S-1 flip in September for a Q4 listing is a real, dateable scenario given typical 3–6 month confidential-review timelines from May 21. The critique's point about resolution ambiguity is fair but cuts mostly toward the market's stricter reading, since Kalshi would likely have resolved already in May under a loose interpretation. Competitive urgency from Strava/WHOOP adds modest upside offsetting the crowded-queue drag. I settle marginally above both the anchor and the two identical 18% forecasts at 19% YES.

Total pipeline time: 260.5s